Christine Ann Miller

Christine Miller is President/CEO, Melinta Therapeutics where she is accelerating its transformation and redefining the portfolio strategy from pure play antibiotics to become a leader in the hospital acute care space. Christine has ensured the FDA approval for KIMYRSA™ (Oritavancin) and REZZAYO™ (rezafungin for injection). She has also secured 3 partnerships: in-licensing of rezafungin from Cidara Therapeutics for exclusive commercialization in the US; licensing agreements to commercialize anti-infectives in Canada with Xedition and Middle East and North America with Hikma. Christine held progressive leadership roles culminating in Global Head of Portfolio – Enterprise at Sandoz, a division of Novartis. She managed the company’s global and US product portfolio and has been involved in 20 different product acquisitions; has launched more than 50 new products. Christine is Board Chair of the Antimicrobials Working Group (AWG). She also serves on the board of BioNJ and recently completed service as a Board Director for biopharma company, Iveric Bio. Christine earned a BA in Chemical Engineering from Rensselaer Polytechnic Inst., holds an MBA in Technology from Stevens Institute of Technology.

Please note that speakers provide their own biographies and headshots. Biographies represent the role of the person at the time of their engagement and are not independently verified by the Milken Institute.